Personal CFO Solutions LLC Buys 6,643 Shares of Medtronic PLC $MDT

Personal CFO Solutions LLC lifted its stake in Medtronic PLC (NYSE:MDT) by 60.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 17,689 shares of the medical technology company’s stock after acquiring an additional 6,643 shares during the quarter. Personal CFO Solutions LLC’s holdings in Medtronic were worth $1,546,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of MDT. Lodestone Wealth Management LLC bought a new position in Medtronic in the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC raised its stake in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Monetary Solutions Ltd bought a new stake in shares of Medtronic during the 4th quarter worth approximately $27,000. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic in the 4th quarter valued at approximately $29,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Medtronic in the 4th quarter valued at approximately $29,000. Institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Down 2.1%

Shares of Medtronic stock opened at $82.06 on Thursday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The business has a fifty day simple moving average of $79.01 and a two-hundred day simple moving average of $88.67. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a market capitalization of $105.04 billion, a price-to-earnings ratio of 22.00, a P/E/G ratio of 2.25 and a beta of 0.56.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. The firm had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be paid a $0.72 dividend. This is an increase from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on MDT shares. Argus lowered their target price on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Monday, April 6th. BTIG Research upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Wednesday, June 3rd. The Goldman Sachs Group decreased their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. Rothschild & Co Redburn lowered their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Finally, Mizuho dropped their target price on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $98.96.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).